Krankenhaus Agatharied
Hausham, 83734, Germany
Location status: Recruiting
Location contact
Peter PB Busch, Dr.
CONTACT
Thomas TA von Ahnen, Dr.
CONTACT
NCT Number: NCT04845867
After thyroid surgery, 0.6 to 4% of patients develop postoperative bleeding. 90% of this postoperative bleeding occurs within the first 48 hours. Most of the time, the complications are rapidly progressing and require immediate attention. Up to 0.6% of patients with postoperative bleeding die. In a clinical study with postoperative pressure measurements it could be shown that postoperative bleeding without interruption leads to a continuous increase in pressure in the neck, as is observed when coughing and pressing. Systematic invasive pressure measurement in the thyroid compartment after surgery might detect a continuous increase in pressure which is often caused by a growing haematoma, indicating serious post-surgery bleeding at a much earlier time compared to state of the art diagnostic workflow. n routine clinical care, detection of serious haemorrhage depends on the patients alerting symptoms even if post-operative intermittent monitoring of vital parameters and wound conditions is performed according to current medical guidelines and local instructions. Device-based, continuous haemorrhage detection within 36 to 48 hours after surgery would allow to objectively measure an increase in cervical pressure before symptoms occur, i.e. early detection of risk leading to timely therapeutic actions. Thus, the risk of serious complications like hypoxic brain damage and death caused by post-operative haemorrhage is minimized. In addition, the intervention team would be able to fine-tune necessary actions during the rescue procedure based on objective pressure values, e.g. the decision to open cutaneous sutures immediately or later in the operation theatre, and therefore reduce additional perioperative morbidity and increase patients' safety.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Hausham, 83734, Germany
Location status: Recruiting
Peter PB Busch, Dr.
CONTACT
Thomas TA von Ahnen, Dr.
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A diagnostic device for early detection of haemorrhage following thyroid surgery
Time frame: within 48 hours following thyroid surgery
detection of clinically relevant haemorrhage compared to the gold standard of detection in routine clinical care using 15 mmHg as cut-off
Time frame: within 48 hours following thyroid surgery
Sensitivity and specificity of detection of clinically relevant haemorrhage within 48 hours following thyroid surgery compared to the gold standard of routine clinical care detection in a three-level decision system using 10 and 20 mmHg as cut-offs
Time frame: within 48 hours following thyroid surgery
Specificity as well as positive and negative predictive values of detection of clinically relevant haemorrhage within 48 hours following thyroid surgery compared to the gold standard of detection in routine clinical care using the two-level and the three-level decision system.following thyroid surgery compared to the gold standard of routine clinical care detection in routine clinical care using the two-level and three-level decision system
Time frame: 1 month
Safety of the use of ISAR-M THYRO by means of adverse events within 1 month following thyroid surgery
Contact information is provided by the study sponsor or research team.
Olivia Fedunik-Brehm
CONTACT
Sabrina Koschel
CONTACT
ISAR-M GmbH
Industry
Thyroid HEmorrhage DetectOr Study
Acronym: HEDOS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04571736
Endocrine System Diseases, Thyroid
Montpellier, Hérault, France
View Trial DetailsNCT05733013
Endocrine Gland Neoplasms, Endocrine System Diseases
New York, United States
View Trial DetailsNCT04615988
Avitaminosis, Cancer
New York, United States
View Trial DetailsNCT06455371
Endocrine Gland Neoplasms, Endocrine System Diseases
Bergen, Norway
View Trial Details